TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teladoc Health Inc (TDOC) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown some positive momentum in the short term, the overbought RSI, lack of significant trading signals, and mixed analyst ratings suggest caution. Additionally, there are no recent positive news catalysts or financial data to support a strong buy recommendation.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 82.128, signaling the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 7.91 and 8.23, with support at 6.875 and 6.555. The stock closed at 8.07, slightly above the first resistance level.
The stock has shown a 6.32% increase in regular market trading, and analysts from Goldman Sachs recently raised the price target to $8 with a Buy rating. BetterHelp, a segment of the business, has shown better-than-expected results.
The RSI indicates the stock is overbought, suggesting limited immediate upside potential. Analysts' ratings are mixed, with some downgrades and reduced price targets. Hedge funds and insiders are neutral, with no significant trading trends. No recent news or congress trading data is available to act as a catalyst.
No financial data or valuation information is available for the latest quarter, making it difficult to assess the company's growth trends.
Analysts have mixed ratings. Goldman Sachs raised the price target to $8 with a Buy rating, while other firms like Stifel and Barclays have lowered their price targets and maintain neutral or hold ratings. The sentiment is cautious due to competitive risks and a transitioning business model.
